Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard ...

The frontMIND trial randomly assigned 899 adults (International Prognostic Index score 3-5; ECOG performance status 0-2) to six 21-day cycles of tafasitamab plus lenalidomide and R-CHOP ...

Learn how to create a beautiful handmade ring step by step with this simple and satisfying jewelry tutorial. Perfect for beginners and DIY jewelry lovers. #JewelryMaking #DIYRing #HandmadeJewelry ...

Antigen-presenting cells activate invariant natural killer T (iNKT) cells, and this combination with α-galactosylceramide subsequently activates the body’s own T cells to fight tumors. This image was ...

Subcutaneous mosunetuzumab with step-up dosing plus six cycles of polatuzumab vedotin enabled fully outpatient delivery without mandatory hospitalization, aligning with access and cost-reduction goals ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. The longtime Tiffany & Co.

Combo Devils, a recently kickstarted platform fighter from developer Punkzilla, has one of the best elevator pitches of any fighting game I’ve played in a hot minute: What if we took the core of Smash ...

Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Findings showed the trial met its primary endpoint demonstrating a statistically significant and clinically ...

Private equity firm Cinven is considering a sale of German software company think-cell, which could be valued at as much as €3 billion ($3.5 billion) in a deal, according to people familiar with the ...